Literature DB >> 2111028

Actions of ORG 5222 as a novel psychotropic agent.

B Costall1, A M Domeney, M E Kelly, R J Naylor, D M Tomkins.   

Abstract

ORG 5222 is a tetracyclic compound with high affinity for dopamine and 5-HT2 receptors. ORG 5222 was compared to fluphenazine in behavioural tests and was shown to be less potent to cause catalepsy on peripheral administration or to induce asymmetric body posturing following intrastriatal injection. On injection into the nucleus accumbens, ORG 5222 antagonised spontaneous and amphetamine-induced hyperactivity. The peripheral administration of ORG 5222 antagonised the hyperactivity induced by infusion of dopamine into the nucleus accumbens of rat or ventral striatum of the marmoset and, unlike the use of fluphenazine, there was no evidence of a 'rebound' hyperactivity after discontinuation of treatment. Furthermore, ORG 5222 prevented changes in responsiveness to dopamine agonist challenge following dopamine infusion. In a mouse black and white test box and the rat elevated plus maze ORG 5222 released exploratory behaviour suppressed by the aversive white or elevated environments. It is concluded that ORG 5222 is effective to antagonise mesolimbic dopamine function in the rodent and primate and an aversive behaviour in rodent tests. Such effects reveal a novel profile of action of ORG 5222 in behavioural paradigms predictive of antipsychotic and anxiolytic potential and may relate to a dopamine and 5-HT receptor antagonism.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2111028     DOI: 10.1016/0091-3057(90)90298-v

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  5 in total

Review 1.  Evaluation of the clinical efficacy of asenapine in schizophrenia.

Authors:  Arpi Minassian; Jared W Young
Journal:  Expert Opin Pharmacother       Date:  2010-08       Impact factor: 3.889

Review 2.  Predictive animal models of mania: hits, misses and future directions.

Authors:  Jared W Young; Brook L Henry; Mark A Geyer
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

3.  Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia.

Authors:  Olivia Frånberg; Charlotte Wiker; Monica M Marcus; Asa Konradsson; Kent Jardemark; Björn Schilström; Mohammed Shahid; Erik H F Wong; Torgny H Svensson
Journal:  Psychopharmacology (Berl)       Date:  2007-10-17       Impact factor: 4.530

4.  Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms.

Authors:  Olivia Frånberg; Monica M Marcus; Vladimir Ivanov; Björn Schilström; Mohammed Shahid; Torgny H Svensson
Journal:  Psychopharmacology (Berl)       Date:  2009-02-07       Impact factor: 4.530

5.  Simultaneous determination of asenapine and valproic acid in human plasma using LC-MS/MS: Application of the method to support pharmacokinetic study.

Authors:  Ambavaram Vijaya Bhaskar Reddy; Nandigam Venugopal; Gajulapalle Madhavi
Journal:  J Pharm Anal       Date:  2013-05-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.